The role of hypoxia-inducible factors in cardiovascular diseases
The role of hypoxia-inducible factors in cardiovascular diseases
复制标题
缺氧诱导因素在心血管疾病中的作用
DOI：
10.1016/j.pharmthera.2022.108186
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Aijuan Qu
中科院分区：
文献类型：
--
作者：
Baoqi Yu;Xia Wang;Yanting Song;Guomin Xie;Shiyu Jiao;Li Shi;Xuejie Cao;Xinyao Han;Aijuan Qu
心血管疾病是全世界死亡的主要原因。在心血管疾病的发展过程中，缺氧起着至关重要的作用。低氧诱导因子（Hypoxia-inducible factors，HIF）是适应性低氧反应的关键转录因子，参与调节血管生成、红细胞生成、糖酵解代谢、炎症等多种基因的转录，近年来的研究揭示了细胞特异性HIF在高血压、动脉粥样硬化、主动脉瘤、肺动脉高压、和心力衰竭。更重要的是，几种开发为HIF抑制剂或激活剂的化合物已在临床试验中用于治疗肾癌或贫血;然而，对这些抑制剂对心血管疾病的治疗潜力知之甚少。本文综述了近年来HIF在心血管疾病发病机制和病理生理中的研究进展，并为临床寻找潜在的治疗靶点提供依据。
Cardiovascular diseases are the leading cause of death worldwide. During the development of cardiovascular diseases, hypoxia plays a crucial role. Hypoxia-inducible factors (HIFs) are the key transcription factors for adaptive hypoxic responses, which orchestrate the transcription of numerous genes involved in angiogenesis, erythropoiesis, glycolytic metabolism, inflammation, and so on. Recent studies have dissected the precise role of cell-specific HIFs in the pathogenesis of hypertension, atherosclerosis, aortic aneurysms, pulmonary arterial hypertension, and heart failure using tissue-specific HIF-knockout or -overexpressing animal models. More importantly, several compounds developed as HIF inhibitors or activators have been in clinical trials for the treatment of renal cancer or anemia; however, little is known on the therapeutic potential of these inhibitors for cardiovascular diseases. The purpose of this review is to summarize the recent advances on HIFs in the pathogenesis and pathophysiology of cardiovascular diseases and to provide evidence of potential clinical therapeutic targets.